Cancer Communications
indexed by SCI

About the cover
About the cover

Feb. 2016; Volume 35 Issue 2

February 27, 2004, Roche announced that Genentech has received approval from the US Food and Drug Administration (FDA) for Avastin (bevacizumab, rhuMAb-VEGF), an innovative new cancer drug, to be used with intravenous 5-Fluorouracil-based chemotherapy as treatment for patients with previously untreated metastatic cancer of the colon or rectum (first-line treatment).

Special series on tumor angiogenesis  

Forming efficient vasculature network, also known as tumor angiogenesis, is a critical hallmark in tumor development. Explorations on its underlying molecular mechanisms have resulted in several novel anti-cancer drugs approved by the Food & Drug Administration (FDA) of the United States. However, the modest survival benefits from anti-angiogenic therapy have forced us to revisit our understanding on tumor angiogenesis. In this special issue of the Chinese Journal of Cancer (CJC), the world leading experts in pathology, molecular biology, pharmacology, and clinical study have contributed their critical thoughts and insightful investigations from different angles to reveal the alternative tumor angiogenesis approaches and potential treatment targets. This special issue is therefore initiating a new era in tumor angiogenesis research, aiming to develop next-generation anti-angiogenic targeted therapy.

Edited by Francesco Pezzella and Chao-Nan Qian

Twenty years after: the beautiful hypothesis and the ugly facts
Francesco Pezzella, Kevin Gatter and Chao-Nan Qian
[ Abstract  1134]  [ PDF Full-text  1238]   [ HTML Full-text  491]    Epub: 2016-2-24  doi: 10.1186/s40880-016-0087-1
Mechanisms of vascularization in murine models of primary and metastatic tumor growth
Edina Bugyik, Ferenc Renyi-Vamos, Vanessza Szabo, Katalin Dezso, Nora Ecker, Andras Rokusz, Peter Nagy, Balazs Dome and Sandor Paku
[ Abstract  4139]  [ PDF Full-text  7629]   [ HTML Full-text  736]    Epub: 2016-2-12  doi: 10.1186/s40880-016-0083-5
Future options of anti-angiogenic cancer therapy
Yihai Cao
[ Abstract  1896]  [ PDF Full-text  2448]   [ HTML Full-text  943]    Epub: 2016-2-18  doi: 10.1186/s40880-016-0084-4
Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation
Chao-Nan Qian, Min-Han Tan, Jun-Ping Yang and Yun Cao
[ Abstract  2040]  [ PDF Full-text  2403]   [ HTML Full-text  633]    Epub: 2016-1-8  doi: 10.1186/s40880-015-0070-2
Original Article
Why some tumours trigger neovascularisation and others don’t: the story thus far
Omanma Adighibe, Russell D. Leek, Marta Fernandez-Mercado, Jiangting Hu, Cameron Snell, Kevin C. Gatter, Adrian L. Harris and Francesco Pezzella
[ Abstract  1840]  [ PDF Full-text  2327]   [ HTML Full-text  917]    Epub: 2016-2-12  doi: 10.1186/s40880-016-0082-6
Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog
Shan Wang, Yan Fu and Yongzhang Luo
[ Abstract  1988]  [ PDF Full-text  2283]   [ HTML Full-text  463]    Epub: 2016-1-20  doi: 10.1186/s40880-016-0080-8

CJC Wechat 微信公众号



Editorial Manager

CC adopts Editorial Manager to manage its submissions from Dec.18, 2014


Reference style for  

 Reference Manager

Editorial Manager





Advanced search


CJC is now published by BioMed Central

© Chinese Journal of Cancer

Sun Yat-sen University Cancer Center

651 Dongfeng Road East, Guangzhou 510060, P. R. China